OOIR: Observatory of International Research

Papers

(The TQCC of Alzheimers & Dementia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Speed of cognitive decline in biomarker stratified SCD subgroups	2522
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	1819
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum	1484
Automating the verbal paired associates test to assess memory remotely and at scale	1440
Regional correlation analysis between neuronal metabolism and synaptic density using [18F]FDG and [11C]UCB‐J	657
Using an entorhinal cortex‐based virtual reality navigation task to differentiate between individuals with and without subjective cognitive decline	453
A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau	369
Transient CSF1R Inhibition in the Early Stage of AD Retains Homeostatic Microglia with Reduced Inflammasomes and Increased autophagy in the 5XFAD Model	363
Short antibiotic treatment followed by regular administration of acid suppressant (proton pump inhibitor) reduce AB42 load in the brain and in the gut.	289
A Placebo‐Controlled Phase I Study in Healthy Subjects Assessing NVG‐291, which Targets CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ)	218
Neuropathology of a patient with AD treated with low doses of verubecestat	192
β‐secretase inhibition prevents structural spine plasticity deficits in AppNL‐G‐F mice	185
TREM2 Burden associates solely with Alzheimer’s Disease, and decreases the Chance to become a Centenarian	173
Whole‐exome sequencing of a Portuguese cohort of early‐onset Alzheimer’s disease implicates X‐linked lysosomal gene GLA	172
Association of Epigenetic Aging with Cognitive Aging in Diverse Hispanics/Latinos	170
Human postmortem studies as a driver of biomarker development	155
Exploring the role of brain DNA methylomic signatures on gene expression dynamics of frontotemporal lobar degeneration	150
Widespread transposable element dysregulation in human brains with Alzheimer’s disease	143
Validated, unified theory of Alzheimer Disease illuminates two essential research questions	135
Dynamic Light Scattering Spectroscopy as an Early Biomarker of Alzheimer’s Disease	130
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly	126
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	124
Addressing the gaps of the functional neuroimaging in young APOEe4 carriers: A systematic review and Graph Theoretical analysis of brain connectivity	123
Cerebral Small Vessel Disease and Gait Speed in Older Adults without Dementia	121
Development of an artificial intelligence approach that employs genomic and brain imaging features to improve the diagnosis of Alzheimer’s Disease (AD)	116

Automated word class and person usage metrics as markers of Alzheimer’s and frontotemporal dementia	113
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	108
Antagonistic Amyloid‐β and tau interactions with T1‐weighted/T2‐weighted magnetic resonance ratio in Alzheimer’s disesase continuum	105
White matter hyperintensities: A long‐term consequence of repetitive head impacts?	104
CASBA neurological assessment: Noninvasive EEG biomarkers classify amyloid‐PET, clinical diagnosis, cognitive dementia rating, and FCSRT free recall scores in patients with cognitive decline	101
Anti‐ulcer drug teprenone clinical trial	96
PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementia	95
WVE‐005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies	92
Synthetic FDG‐PET hypometabolism sensitivity validation in AD	89
Reconsideration of appropriate use criteria for amyloid PET based on real‐world experiences	88
CSF Biomarkers and [¹⁸F]flutemetamol PET‐Derived Centiloids in Patients with SCD or MCI	86
Brain‐Penetrable Antibody Probes for in vivo Tau Imaging	85
Cerebral perfusion and amyloidosis in the oldest‐old	85
Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction relat	83
TMS‐based measures of cortical excitability are related to distributed atrophy in early Alzheimer’s disease	83
PAS‐MCI: Design and rationale for a randomized controlled trial to enhance prefrontal cortical plasticity and working memory in individuals with amnestic mild cognitive impairment	80
Combined effect of prebiotic and probiotic strains restores cognitive impairment via attenuating synaptosis in the hippocampus of mice fed with high fat diet and streptozotocin diabetes‐induced dement	78
A 5‐hydroxymethylation‐based clock derived from cell‐free DNA in blood reveals accelerated epigenetic aging in patients with Alzheimer’s disease	78
A portable eye tracking experiment for the assessment of cognitive impairment in presymptomatic frontotemporal dementia	77
Plasma biomarkers, memory impairment, and imaging measures of Alzheimer’s disease in American Indians	76
Observations on biomarkers in Roche Abeta‐targeting monoclonal antibody trials	76
Automated lexical analysis of story recall in healthy controls	75
A retinal tauopathy with a characteristic molecular pattern points to the existence of a “Primary retinal tauopathy”	75
Determination of molecular chaperone levels in cerebrospinal fluids of Alzheimer’s patients	74
Explainable AI and its instantiation in Computational Pathology for a better understanding of Alzheimer’s disease	74
The App^NL‐G‐F/MAPT mouse model of Alzheimer’s Disease demonstrates increased levels of ptau217 in CSF, changes that correlate with increased cerebral p‐tau depositions	74
Perceptions of Shared decision making in cognitive impairment of LTC recipients	73
Baseline and Six‐Month Actigraphy and Sleep‐monitoring Devices Help Differentiate Between Alzheimer’s Disease and Dementia with Lewy Bodies	73
Elderly Role Performance Occupational Therapy	73
Plasma phosphorylated tau 181 and modifiable risk factors for dementia in a large scale cohort of Australian older adults	73
Exploring Narrative Identity via Linguistic Positioning in the Context of Alzheimer’s Dementia Risk Prediction – an Ethical and Linguistic Analysis	72
Longitudinal patterns of behavioral and psychological symptoms of dementia in community‐dwelling older people	72
Impact of the COVID‐19 Pandemic on Patients with Dementia or Parkinson’s Disease and their Caregivers in Lima, Peru	70
A 10‐minute Digitally Administered and Scored Neuropsychological Protocol Assessing Executive Control and Episodic Memory	69
A Study of Factors Influencing Quality of Life among Community Dwelling Elderly in Korean Urban Community	69
Tolerability and Likeability of a Cognitive Training Program in an Outpatient Memory Care Clinic	69
Decline in everyday functioning in relation to cerebral tau burden across the clinical spectrum of Alzheimer’s disease	68
Identification of objective cognitive decline in preclinical Alzheimer’ disease	67
Comparing associations of Alzheimer’s disease plasma biomarkers with remote self‐administered cognitive measures versus in‐person neuropsychological tests	65
Unsupervised Learning‐based Drug Repositioning for Alzheimer’s Disease Targeting Brain Cell Type Specific Genetic Subtypes	65
Incorporating clinical trial outcomes in health economic evaluations of disease‐modifying therapies for AD	64
Preliminary Evidence for the Combined Efficacy of Focused Ultrasound Blood‐Brain Barrier Opening and Delivery of a Novel Anti‐Amyloid Re Complex for Memory Improvement in a 3xTg‐Alzheimer’s Disease Mo	63
Clinical outcome assessments for LBD trials – Should we borrow?	63
Microglial‐targeted nSMase2 inhibitor fails to reduce tau spread in the animal model of Alzheimer’s disease	62
Issue Information	62
Study Design of FINGER‐NL: a Multidomain Lifestyle Intervention in Dutch Older Adults to Maintain Optimal Cognitive Functioning	61
Comparative efficacy of cholinesterase inhibitors and memantine on cognition in AD patients with application of network meta‐analysis	60
The association between air pollution and dementia: results from the Cognitive Function and Ageing Study II and Wales	60
Development of pyroptosis inhibitors for Alzheimer’s disease	59
Impact of Mid‐ and Late‐Life Diabetes in the Trajectories of Cognitive Aging in a Bi‐ethnic Cohort of Mexican Americans and Non‐Hispanic White Older Adults	58

Impact of Site Size on Data Quality in Early Alzheimer’s Disease Clinical Trials	58
Analytical Choices of Timescale in the Presence of Practice and Cohort Effects in Longitudinal Cognitive Aging Research: A Simulation Study Using Linear Mixed‐Effects Models	58
CD33 competitive inhibitor peptide IMAD‐001 modulates innate immunity in Alzheimer’s disease	58
Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population	58
Delivery of incretin receptor agonists to the brain	58
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology	57
Cognitive impairment prevention and healthy aging. A multidisciplinary team work	57
A Rule‐Based Framework to Identify Severity of Dementia from Unstructured Electronic Health Record Data	57
Comparison of Vascular Health in Super‐Agers and Cognitively Normal Adults 80 Years and Older	57
	56
Prevalence of risk factors for dementia and association with cognitive alterations in an elderly population from the South of Brazil	56
Preventing cognitive decline using portable, non‐invasive sleep enhancement.	56
Recruitment data of the HAPPCAP‐AD (Human‐APPlication Combined Approach for Prevention of Alzheimer’s Disease): a feasibility study	54
COVID‐19 Infection and Dementia: Analyses of time‐varying risk, subtypes, and subpopulations from the UK Biobank	54
Inflammation and working memory performance in everyday life: Gender differences among older adults with and without cognitive impairment	54
Sex modifies the associations of regional fat with cognitive functioning and AD‐related brain volumes, in Israeli middle‐aged adults at high AD risk	54
A Comparison of the Prevalence of Diabetes between Aging Rural and Urban Indians.	54
Transition in the cognitive continuum from normal cognition to dementia: the interplay of lifelong cognitive reserve with brain aging and genetic predisposition	53
Characterising the covariance pattern between lifestyle factors and structural brain measures: a multivariable study of two cohorts of older adults	53
Cognitive symptoms and medical history prior to mild cognitive impairment and dementia diagnosis: a retrospective case‐control study using Dutch primary care data	52
Reducing Risk of ADRDs: Innovative Framework to Inform Behavior Change	52
Social media responses to the approval of lecanemab in Japan: sentiment analysis	51
Impact of Metabolic Syndrome Longitudinal Changes on Cognitive Health: A 10‐Year Follow‐up Study in Middle‐Aged Adults	51
Relation Between Educational Attainment and Cerebral Small Vessel Disease: the Framingham Heart Study	51
Additive Impact of Cardiometabolic Multimorbidity and Depression on Cognitive Decline: Findings from Multi‐Regional Cohorts and Generalization from Community to Clinic	51
Are there trends towards compression of morbidity for dementia? Evidences from four international population‐based cohorts	51
Improvement of Knowledge and Research Attitudes on Preclinical Alzheimer’s Disease Trials through Community‐based Education Among Underrepresented Korean, Filipino, and Hispanic Americans	51
Social Engagement is associated with better cognition in Quilombola Communities: Insights for Engaging underserved Brazilian Populations in Alzheimer’s Disease Research	50
Engaging and Recruiting Latino‐led Community Organizations to Build Workforce Capacity in AD/Brain Health Prevention Research	50
Integrated analysis of in vivo retinal perivascular amyloid imaging and cognition	50
Baseline Frailty and Domain‐specific Cognitive Declines in Healthy and MCI Older Adults	50
Microvascular Morphology MR Imaging Using Relaxation Rate Change with Gadolinium‐Based Contrast Agent in Patients with Alzheimer’s Disease	49
Short‐term Sirolimus Treatment Restores Hippocampus and Caudate Volumes and Global Cerebral Blood Flow in Asymptomatic APOE4 Carriers Compared with Non‐carriers	49
High Social Deprivation as a Risk Factor for Dementia: Findings from the longitudinal SHARE study of older Europeans	49
Correction to “Using remote, digital, multi‐day testing to characterize long‐term forgetting in cognitively unimpaired older adults”	49
The moderating effect of APOE E4 on the association of plasma biomarkers with markers of cognition and brain health in Alzheimer’s disease	49
The potential protective benefit of personality on subjective cognitive decline related worry: Results from the Canadian Longitudinal Study on Aging (CLSA)	48
Tau‐PET imaging with ¹⁸F‐PI‐2620 reveals lateralized distribution of tau pathology in critical language regions in patients with early onset of Alzheimer’s Disease and patients with primary	48
Diffusion MRI subnetwork efficiency is associated with cognitive resilience to AD pathology in cognitively unimpaired older adults at risk of AD dementia	48
Innovative Methods to Gather, Understand, And Incorporate Diverse Lived Experiences Into Dementia Research	48
Bibliographic Analysis of Aging Anxiety and Lifestyle	48
Applying novel EMBRACE technological solutions to measure and optimize brain response to exercise.	47
Racial differences in white matter hyperintensity load in aging, MCI, and AD	46
Differential Effects of Anticholinergic Medications in a Human Neuronal Model of AD	46
Racial disparities in Alzheimer’s Disease (AD): Correlating a novel neuropsychological screening test to established AD fluid and imaging biomarkers in African Americans and Caucasians	46
Plasma GFAP:NfL discriminates FTLD‐tau from FTLD‐TDP	46
How well is Brazil prepared for a disease‐modifying Alzheimer’s treatment?	46
Amyloid‐β Pathology Exacerbates Aging‐Induced Dysregulation of C1q Expression in Cortical Neurons	45
Association between plasma inflammatory biomarkers and [¹⁸F]FDG‐PET signal in a transgenic amyloid rat model	44
Syzigium aromaticum may protect against paraquat mediated toxicity via p53 and Sestrin2 modulation	44
Impaired retinal capillary function in patients with clinical Alzheimer’s disease	44
Ameliorative effects of Aqueous Fruit Pulp Extracts of Adansonia digitata on the Hippocampus of Aluminium Chloride‐treated Adult Wistar Rats	44
Relationships between cerebral tau and glucose metabolism in cognitively normal older adults	43
Prevalence and pathological correlates of unawareness of memory impairment in non‐demented individuals with autosomal dominant Alzheimer’s disease: an item‐level investigation of the Memory Complaints	42
APOE loss‐of‐function variants: Compatible with longevity and associated with resistance to Alzheimer’s Disease pathology	42
The effect of virtual reality and physical exercise training on cognitive function in older adults with mild cognitive impairment	42
Clinical profile of primary progressive Aphasia in Peru: Case series from a Neurological care center	42
Risk knowledge and risk perception of MCI patients and their caregivers in predictive diagnosis of AD: Findings from the PreDADQoL study	42
Is QEEG an effective biomarker in predicting cognitive decline?	42
Depression in Alzheimer’s disease hospitalized patients: A descriptive analysis of a nationwide database	42
Associations between blood‐based biomarkers and other outcomes related to Alzheimer’s disease	42
Premature aging in co‐occurring Alcohol Use Disorder and Post‐Traumatic Stress Disorder from a functional connectome perspective	41
	41
CSF tau phosphorylation at sites 217 and 181 are associated with preclinical and biphasic alterations in resting‐state functional connectivity in Autosomal Dominant AD	41
Hub vulnerability and short path length to entorhinal cortex are associated with tau binding in Alzheimer’s disease: a combined MEG/PET study	41
Recognizing human functional patterns in IADLs through hand detection and artificial intelligence	41
Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum	40
Amyloid‐Beta PET Synthesis from Structural MRI: A Potential Alternative Method for Alzheimer’s Disease Screening	40
APOEε4 facilitates the accumulation and connectivity‐mediated spreading of tau pathology at lower amyloid levels	40
The Advanced Therapeutics for Alzheimer’s Disease Review Board: A Multidisciplinary Model to Facilitate Safe Access to Lecenemab across the Sutter Health System	40
Usability experience of remote sleep monitoring in patients with neurodegenerative diseases	40
Hyperintensity on Diffusion‐Weighted MRI and Clinical Correlations in Probable Creutzfeldt‐Jakob Disease	40
Glial and synaptic biomarkers as early indicators of mild cognitive decline	39
Association of the learning ratio with AD biomarkers after application of actuarial diagnostic criteria to ADNI cognitively normal participants	39
Lithium carbonate treatment decrease neuroinflammation and ameliorates long‐term memory in a Down syndrome animal model	39
Motor alterations associated with cognitive impairment in a third‐level hospital	39
A passive, neural correlate of verbal fluency in Mild Cognitive Impairment using Fastball neurocognitive assessment	39
Issue Information	39
Comparison of histological delineation of the entorhinal, perirhinal, ectorhinal, and parahippocampal cortices by different neuroanatomy laboratories	39
Developing a preference‐based quality of life for people living with dementia in Vietnam	39

A Machine Learning Approach to Identify Individualized Baseline MRI, Plasma, Cardiovascular and Lifestyle Predictors of a 5‐Year Cognitive Decline	39
Description of the Gut Microbiome Composition in Puerto Ricans with Alzheimer’s Disease Compared to Healthy Controls	39
The role of clusterin and the variant rs11136000_T throughout the spectrum of Alzheimer’s disease	39
A cluster randomized trial: Exploratory quantitative analysis comparing resident outcomes for two approaches to promote non‐pharmacological, resident‐centered dementia care in nursing homes	39
Seizures exacerbate tau spread in the 5XFAD mouse model	39
Movement with Dementia: A feasibility study of a resource to support the personalisation of therapeutic exercise programmes for people living with dementia	39
Understanding differences in antidepressant use patterns among african american and white volunteers with dementia	39
Complement receptor 1 length polymorphism impacts glial functions relevant to Alzheimer’s disease	38
Testamentary Capacity Assessment Tool (TCAT): An update report	38
Increased fibrin deposition in the brains of individuals with Down syndrome and Alzheimer’s disease	38
Expanded bile acid annotations linked to diet and AD biomarkers	38
The role of impaired oxidative base lesion repair in Alzheimer’s disease	38
Sex and APOE differences in Alzheimer’s Disease‐On‐Ramp risk factor profiles: Are all risk factors for Alzheimer’s Disease created equal?	38
Proteomics identification of novel proteins dysregulated in Alzheimer’s Disease with potential as blood‐based biomarkers and related to Amyloid‐Beta Plaques	38
Production and characterization of human tau protein with site‐specific phosphorylation utilizing E. coli with an expanded genetic code	38
Interaction between polymorphisms in MBP and EIF2B5 genes is significantly associated with Alzheimer’s disease	38
A comprehensive literature search of digital health technology use in dementia: Digital tools to support dementia caregivers	38
Dynamic disease‐associated gene regulatory transitions unmask genetic risk associated neurodegenerative cell states	38
Persistent DNA damage response drives cGAS‐STING mediated neuroinflammation in a mouse model of tauopathy	38
Whole blood DNA methylation profiles of Alzheimer’s disease differ across ancestrally diverse populations	38
PENSA study for the prevention of cognitive decline in APOE‐ɛ4 carriers with subjective cognitive decline: Description of baseline demographic and neuropsychological data of the study population	37
Multiple pathological mechanisms of Bin1 for tau aggregation and propagation	37
Language, cognitive and neuroimaging determinants of Primary Progressive Aphasia in Hebrew Speakers, a case series	37
Bin1 regulates synaptic endocytic trafficking compromised by Alzheimer’s genetic risk variants	37
Who is at risk of dementia? Trajectories of cognitive decline from mild cognitive impairment to dementia and the factors which mediate this decline	37
EEG microstates as a “real time” feedback for rTMS treatment efficacy in MCI subjects	36
Integrative Analysis of Genetic Network and Brain Imaging using Generative Models for Alzheimer’s Disease Prediction	36
Retinal Examination in Neurodegenerative Diseases of the Brain	36
Hypogyrification in midlife women with surgical menopause, a population at risk for late life Alzheimer’s	36
Anosognosia and caregiver distress independently identify subjects at high risk of developing dementia of Alzheimer’s type	36
Associations between imaging biomarkers and sleep quality in the U.S. POINTER study baseline cohort	35
Prevalence of dementia diagnoses in a safety net health system	35
CSF biomarkers trajectories across the AD spectrum reveal the temporal dynamics of amyloid and tau	35
Combining high‐resolution ex vivo MRI and histopathology to identify medial temporal lobe atrophy patterns specific to tau pathology in Alzheimer’s Disease	35
Neurobiological correlates of grey matter morphometry changes in preclinical Alzheimer’s disease	35
Targeted Multiplexed MALDI MS Platform Enables Detection of Novel Pathogenic Forms of Tau, Amyloid Beta and Alpha Synuclein	35
Cardiorespiratory fitness is an important marker of cognitive performance in older Latin Americans	35
Aberrant resting‐state functional connectivity of the default‐mode network relates to cognitive decline in the earliest Alzheimer’s continuum	34
Ancestry‐Specific eQTL Associations in AA/NHW Alzheimer Disease Cohorts	34
Family care partners experiences of delirium in caring for a person with dementia: Qualitative descriptive study	34
Contrast of Early Phase Amyloid PET	34
Addressing the gaps of the functional neuroimaging in young APOEe4 carriers: A systematic review and Graph Theoretical analysis of brain connectivity	34
CaMKIIα signaling is required for the neuroprotective effects of Dl‐3‐n‐butylphthalide in Alzheimer’s disease	33
Methods in Prioritizing Pathways and Targets from Expression Data	33
Re‐evaluation of the genetic role of a rare APOE variant (L28P; APOE^4Pittsburgh*) in late‐onset Alzheimer disease	33
The Effect of COVID‐19 Lockdown on Dementia Caregivers in the U.S.	33
Myelin water imaging with clinically feasible scan time: the accelerated BMC‐mcDESPOT (aBMC‐mcDESPOT) method	33
Loss of apolipoprotein E exacerbates microglial and astrocyte reactivity to sustained systemic glucocerebrosidase inhibition	33
Characteristics of peripheral immune system in a novel App^NL‐G‐F knock‐in mouse model of Alzheimer’s disease	33
2021 Annual Report of Japanese Brain Bank Network for Neuroscience Research	33
Synapse loss in early‐ and late‐onset Alzheimer’s Disease assessed by 18F‐SynVest‐1	33
Deep learning‐based estimation of future brain atrophy using baseline MRI and PET	33
AD‐Associated Variants Directly Impair Surface Interactions Between the Hydrophobic Site of TREM2 and the Hinge Region of ApoE	33
Systemic and central nervous system metabolome changes associated with Ginkgo biloba treatment in non‐demented subjects	33
Intracranial atherosclerosis is linked to lower volume in the posterior portion of the hippocampus	33
Plasma and neuroimaging biomarkers of small vessel disease and Alzheimer’s disease in a diverse cohort	33
	33
Cost‐effectiveness analysis of the multimodal intervention for dementia prevention: post‐hoc sub‐group analyses of the J‐MINT	32
Association between pulmonary function and cognition in urban Indian adults – A cross sectional analysis	32
Comparing the Brief Assessment of Cognitive Health and Montreal Cognitive Assessment: Test‐retest reliability and sensitivity to cognitive change in older adults	32
Socioeconomic and health‐related disparities associated with healthy brain aging in Latin American countries	32
The Relationship of Neuropsychiatric Symptoms and ADRD Pathologies	32
Passively collected smartphone behaviour as a reliable and feasible measure for global cognition in Alzheimer’s Disease	32
Examination of intrapersonal and affective characteristics associated with everyday function among older adults with subjective cognitive decline	32
Association of CSF AD biomakers and lifestyle factors with neuropsychiatric symptoms among non‐demented older persons	32
Standardizing Care for Agitation in Alzheimer’ Dementia: Results from a Randomized Controlled Trial of an Integrated Care Pathway versus Usual Care ‐The StaN trial	32
Assessing Short‐term Memory with Different Memory Modalities in Mild Cognitive Impairment	31
Challenges to Dementia Care in El Salvador: Perspectives from Geriatricians of the Salvadoran Older Adults Study	31
Depressive Symptoms and Cognitive Function in Older Adults with Subjective Cognitive Decline: Longitudinal Findings From 2010 to 2020	31
Simian varicella virus infection in rhesus macaques is associated with amyloid deposition in multiple organs and arteries and production of an amyloidogenic state	31
Cognitive Disparities in the Wayuu Indigenous Population: Insights from Neuropsychological Assessment	31
Fatigue predicts 10‐year risk of incident dementia in a population representative cohort of United States Medicare beneficiaries	31
Modifiable dementia risk factor associations with AT(N) biomarkers: Findings from the European Prevention of Alzheimer’s Dementia study	31
Utility of two computerized assessments for predicting clinical progression in individuals with early Alzheimer’s Disease	31
Effects of lifestyle factors on Alzheimer’s disease symptoms in adults with Down syndrome	31
Cognitive Impairment in Firefighters and Emergency Medical Services Workers after Severe WTC Exposures	31
Cognitive Complaint, Mild Cognitive Impairment, and Mild Behavioral Impairment as Predictors of Dementia or Alzheimer’s Disease in a Population‐Based Sample: The Cache County Study	31
Examining the Effect of Work‐Life Imbalance on Cognitive Complaints	30
Prevalence of Dementia among Malawian adults with HIV and without HIV: A Medical Record Review	30
Virtual Reality‐based Cognitive and Exercise Intervention for People with Mild Cognitive Impairment. A systematic review and meta‐analysis	30
A predictive regression model for mild cognitive impairment and Alzheimer´s disease using real‐world electronic health records	30
Exploring Social Engagement in a Virtual Participatory Culinary Nutrition Education Intervention for Dementia Prevention	30
Optimizing Mealtime (OPTIMAL): A Pilot Trial of a Person‐Centered Care Program in Nursing Home Care Staff and Residents with ADRD	30
Assessing attitudes and beliefs of dementia risk and prevention in middle‐aged adults	30
Fast and insightful: triage‐level cognitive screening captures risks beyond delirium in emergency care for older adults	30
Lexicon of Dementia: A cross‐linguistic study of the impact of dementia terminology on cultural perceptions	30
Subjective Social Status, Brain Health, and Cognitive Reserve Across Race/Ethnicity and Sex/Gender	30
Dementia Mortality in the United States, 2020‐2022	30
Cardiovascular Health and Cognitive Function in Early Midlife: A Cross‐Sectional Analysis of the 1970 British Cohort Study	30
Predicting Neurodegenerative Diseases: Unveiling the Interplay of Genetics and Social Determinants	29
Evaluating the use of eye tracking tasks as language‐ and culturally‐neutral assessments of cognition in a multi‐ethnic cohort of older adults	29
Differential network‐based propagation of cortical thinning in atrophy subtypes in non‐demented individuals	29
Cerebrovascular injury markers explain the effect of systemic vascular risk on cognitive decline in older adults with lower amyloid burden	29
Transformer‐based Deep Learning Architecture Improves Detection of Associations between Spontaneous Speech Language Markers and Cognition	29
Association of Retinal Layer Thickness with Brain Volume and Cortical Thickness in older adults	29